RxDoctor Payments DataLook up a doctor →

Navin Budhwani, MD

Interventional Cardiology · Oakland, NJNPI 1104990266

Payments from drug & device makers

$62,713in general payments, 2019–2025

Across 620 payments — averaging $101.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$26K
  • Esperion Therapeutics, Inc.$17K
  • Abbott$2K
  • Medtronic$2K
  • Boston Scientific$2K
  • Novartis$1K
  • plus $12K from 45 others

What the payments were for

  • Speaking & faculty fees$39,81863%
  • Travel & lodging$2,7524%
  • Food & beverage$19,85032%
  • Education$2740%
  • Entertainment$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,713 in reported general payments places this provider in the 85th percentile of 166 interventional cardiology providers in New Jersey.

See all interventional cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$1,259,505
Medicare patients
1,080
Services billed
6,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban395$442,129
XareltoRivaroxaban65$86,451
BrilintaTicagrelor81$70,115
JardianceEmpagliflozin43$54,088
Repatha SureclickEvolocumab59$52,480
EntrestoSacubitril/Valsartan39$47,534
Icosapent Ethyl43$20,506
VascepaIcosapent Ethyl32$17,104
OzempicSemaglutide15$15,121
Metoprolol Succinate800$14,632
ClopidogrelClopidogrel Bisulfate484$8,188
Rosuvastatin Calcium580$8,019
Atorvastatin Calcium445$5,789
Diltiazem 24hr Er (Cd)Diltiazem Hcl116$5,392
Dabigatran EtexilateDabigatran Etexilate Mesylate18$4,569

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$461$442,129395 claims
Johnson & JohnsonXarelto$349$86,45165 claims
AstraZenecaBrilinta$580$70,11581 claims
Boehringer IngelheimJardiance$419$54,08843 claims
NovartisEntresto$1,283$47,53439 claims
Novo NordiskOzempic$438$15,12115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 166 interventional cardiology providers in New Jersey.

Other interventional cardiology in Oakland

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →